News
4h
Zacks Investment Research on MSNIs Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...
With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate of $650 per ...
We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential.
The weekly shot that's transforming weight loss journeys. Discover how Zepbound is reshaping obesity treatment and offering ...
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...
A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...
A federal judge in Texas handed Novo Nordisk (NVO) a big win late Thursday in its battle against cheaper versions of its ...
The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...
Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...
A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results